0000899243-20-020912.txt : 20200731 0000899243-20-020912.hdr.sgml : 20200731 20200731183540 ACCESSION NUMBER: 0000899243-20-020912 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200729 FILED AS OF DATE: 20200731 DATE AS OF CHANGE: 20200731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Atillasoy Ercem CENTRAL INDEX KEY: 0001818802 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 201067316 MAIL ADDRESS: STREET 1: C/O ALLOVIR, INC. STREET 2: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-29 0 0001754068 Allovir, Inc. ALVR 0001818802 Atillasoy Ercem C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Common Stock 2020-07-29 4 A 0 75000 0.00 A 75000 D Stock Option (Right to Buy) 17.00 2020-07-29 4 A 0 407400 0.00 A 2030-07-29 Common Stock 407400 407400 D The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 20, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. In the event of the Reporting Person's termination without cause or for good reason, the RSUs shall immediately vest in full. 25% of this option shall vest and become exercisable on July 20, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. Officer Title: Chief Regulatory and Safety Officer /s/ Brett Hagen, as Attorney-in-Fact 2020-07-31